Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
暂无分享,去创建一个
T. Delozier | J. Bonneterre | B. Asselain | M. Campone | J. Canon | A. Monnier | P. Viens | P. Fumoleau | P. Soulié | Anne-Laure Martin | M. Spielmann | P. Kerbrat | J. Ferrero | D. Serin | H. Roché | M. Symann | M. Goudier | A. Vindevoghel | F. Eichler | J. Genève
[1] M. Namer,et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] A. Howell,et al. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] C. Seynaeve,et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] B. Overmoyer,et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Namer,et al. Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] J. Bryant,et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[8] S. Schraub,et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] V. Noronha,et al. Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.
[10] S. Culine,et al. Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer , 2004, British Journal of Cancer.
[11] J. Bonneterre,et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Krzakowski,et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Bonneterre,et al. Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Richard L Schilsky,et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Schraub,et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Ramos,et al. Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study , 2003, Cancer Chemotherapy and Pharmacology.
[17] M. Piccart,et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] T. Delozier,et al. Epirubicin‐Docetaxel Combination in First‐Line Chemotherapy for Patients With Metastatic Breast Cancer: Final Results of a Dose‐Finding and Efficacy Study , 2001, American journal of clinical oncology.
[19] F. Cognetti,et al. Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] Robert J. Mayer,et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.
[21] A. Milla-Santos,et al. High-Dose Epirubicin Plus Docetaxel at Standard Dose With Lenograstim Support as First-line Therapy in Advanced Breast Cancer , 2001, American journal of clinical oncology.
[22] J. Jassem,et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Mackey,et al. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] S. Agelaki,et al. Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] M. Zucchetti,et al. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] A. Wolff,et al. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] V. Diéras,et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] P. Conte,et al. Paclitaxel plus epirubicin in advanced breast cancer. , 1998, Oncology.
[29] M. Untch,et al. Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin. , 1998, Oncology.
[30] P. Dombernowsky,et al. Doxorubicin plus paclitaxel in advanced breast cancer. , 1997, Seminars in oncology.
[31] P M Ravdin,et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] V. Valero,et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] A. Caraceni,et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M. van Glabbeke,et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] P. Armitage,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.